Phasefocus’ Post

ACTIVE loading of vesicles with drugs results in an intra-vesicular drug concentration significantly higher than in the loading medium. For example, the remote loading of liposomes with doxorubicin via an ammonium gradient (the prototype of ACTIVE loading) yields liposomes with drug concentrations inside the liposomes >100-fold the drug level in the loading medium. I severely doubt any of the "active drug loading" methods listed in this paper are able to achieve that. Baring a special interaction of the drug with lipid membranes or components already inside EVs, the intra-vesicular drug concentration can never be higher than in the loading medium, neither by electroporation, sonication, detergent treatment, extrusion nor by freeze-thawing cycles. All these 5 methods lack a driving force leading to an ACCUMULUATION of the drug inside the vesicle. The term "active loading" is wrongly used in this paper. I am happy to be challenged on my opinion, I am open for any discussion and if I am wrong, I would be happy to stand corrected.

Exploring extracellular vesicles as a drug delivery system for cancer therapy: in this review article, Jiabing Lian at China Medical University and collaborators offered a comprehensive overview of extracellular vesicles, detailing their biogenesis and absorption mechanisms. Additionally, they explored current research efforts aimed at utilizing EVs as drug carriers, covering purification techniques, drug loading, and bioengineering for targeted delivery https://lnkd.in/eTCm_t4Z Their analysis highlighted the potential of EVs as versatile and effective tools for drug delivery, especially in cancer therapy. An article co-authored by Jin Wang and Bohang Yin #extracellularvesicles #exosomes #drugdelivery #cancertherapy #bioengineering #Vesiculab

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing

Myeloid cells often suppress immune responses in cancer, creating a major challenge for treatments like checkpoint inhibitors. Targeting these cells could be the breakthrough needed to improve outcomes for more patients. Explore how ME Therapeutics is addressing this challenge: https://lnkd.in/effQ7kG4 #MyeloidCells #CancerResearch #ImmunoOncology #HealthcareInnovation #CheckpointInhibitors #BioTech #TumourResearch #MedicalScience #InnovativeMedicine

Researchers from the Broad Institute of MIT and Harvard, in partnership with Bayer and Trueline Therapeutics, have developed BRD-810, a small molecule drug that inhibits the MCL1 protein. MCL1 blocks apoptosis, a natural cell death process, in various cancer cells. After a decade of research, BRD-810 shows promise in reactivating apoptosis in tumor cells while sparing healthy ones, according to MedicalXpress. Read more: https://lnkd.in/diT4ktBb Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, Harvard University, Bayer | Pharmaceuticals, Trueline Therapeutics, MedicalXpress.co.uk, Nature Portfolio, Mahendra Bhandari, Raj Vattikuti #cancer #CancerResearch #VattikutiFoundation #medicalresearch #HealthcareInnovation #HealthTech #healthcare #CancerAwareness

PBMC-humanized models are invaluable for oncology research, but donor cell variability can cause inconsistent engraftment, tumor growth, and outcomes. Validating engraftment rates, monitoring Graft versus Host Disease, and using recallable PBMC donors ensure uniform, reproducible results for your studies. Learn more by registering for our upcoming webinar Feb. 12, 1pm EST / 10am PST. Register here: https://okt.to/75I8rD #animalmodels #animalresearch #lifesciences #biotech #biotechnology #webinar #research #science #pharmaceuticalindustry #scienceandtechnology #oncology #clinicalreserach #cancer #cancerresearch

📢 Call for Papers in Anti-Cancer Agents in Medicinal Chemistry We're pleased to announce a special issue on the "Discovery of Lead compounds targeting transcriptional regulation", led by Guest Editor Dr. Yihua Chen and Dr. Bo Liu. Novel anticancer compounds targeting transcriptional regulation, crucial for tumor growth, metastasis, and drug resistance. 🗓️ Submission Deadline: December 31, 2025 👉 Submit your manuscript and contribute to shaping the future of cancer therapy! #CancerResearch #DrugDiscovery #Anticancer #MedicinalChemistry #TranscriptionalRegulation #CancerTherapy #TumorProgression #OncologyResearch

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐢𝐞𝐥𝐝 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! The latest research by Christiane R. Stadler and team introduces BNT142, a groundbreaking lipid nanoparticle-formulated RNA encoding a novel bispecific antibody targeting CD3 and the oncofetal antigen CLDN6. This innovative approach has shown promising results in inhibiting tumor growth in preclinical models without causing adverse effects. This was followed by a phase 1/2 clinical trial to evaluate its safety and efficacy in patients with advanced solid tumors. 🚀🔬 #CancerResearch #InnovativeTherapies #MedicalBreakthroughs

Exosomes, nanosized vesicles released from cells, are gaining popularity as drug delivery vehicles due to their ability to escape liver homing and undesired accumulation. Bovine milk/colostrum-derived exosomes, functionalized for cancer therapeutics, show promise, including validation of anti-tumor efficacy. Check out this free webinar by our friends at Spectral Instruments Imaging on June 11, at 10 AM PDT (12 PM CDT / 1 PM EDT), and learn how milk exosomes can be utilized for targeted drug delivery & the latest advancements in RNA & DNA delivery using the Exosome-PEI-Matrix (EPM) technology: https://lnkd.in/dbPmmX-y #Oncology #Exosomes #Milk #Imaging #PreclinicalImaging

DELFI Diagnostics published promising data in the journal Cancer Discovery, outlining the performance and potential of its blood-based #AI test to screen for #lungcancer. https://lnkd.in/de2aS-gv #artificialintelligence #biotechnology #clinicalresearch #DELFIDiagnostics #diagnostics #imaging #IVDs #medicalaffairs #oncology